MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma

Cancer

Volumn 87, Issue 5, 1999, Pages 295-298

  Niemann, Theodore H ^a,c   Hughes, Jonathan H ^b   De Young, Barry R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c E 403 Doan Hall ^*  (United States)

Author keywords

Adenocarcinoma; Fine needle aspiration biopsy; Hepatocellular carcinoma; MOC 31

Indexed keywords

ALCOHOL; AVIDIN; BIOTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOC 31; PARAFFIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; ASPIRATION BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; METASTASIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; LIVER NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0033604283     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991025)87:5<295::AID-CNCR9>3.0.CO;2-1     Document Type: Article

References (21)

1. De Young BR, Proca DM, Porcell AI, Niemann TH. MOC31 immunoreactivity in primary and metastatic carcinoma of liver. Mod Pathol 1998;11:151A.
2. Niemann TH, Miller TR, Bottles K, Cohen MB. Fine needle aspiration biopsy of the liver. In: Schmidt WA, editor. Cytopathology annual 1996. Chicago: ASCP Press, 1996:159-74.
3. Cohen MB, Haber MM, Holly EA, Ahn DK, Bottles K, Stoloff AC. Cytologic criteria to distinguish hepatocellular carcinoma from nonneoplastic liver. Am J Clin Pathol 1991;95: 125-30.
4. Bottles K, Cohen MB, Holly EA, Chiu SH, Abele JS, Cello JP, et al. A step-wise logistic regression analysis of hepatocellular carcinoma. An aspiration biopsy study. Cancer 1988; 62:558-63.
5. Bedrossian CWM, Davila RM, Merenda G. Immunocytochemical evaluation of liver fine-needle aspirations. Arch Pathol Lab Med 1989;113:1225-30.
6. Johnson DE, Powers CN, Rupp G, Frable WJ. Immunocytochemical staining of fine-needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma. Mod Pathol 1992;5:117-23.
7. Nap M, Ten Hoor KA, Fleuren GJ. Cross-reactivity with normal antigens in commercial anti-CEA sera used for immunohistology: the need for tissue controls and absorptions. Am J Clin Pathol 1983;79:25-31.
8. Wong MA, Yazdi HM. Hepatocellular carcinoma versus carcinoma metastatic to the liver. Value of stains for carcino-embryonic antigen and napthylamidase in fine needle aspiration biopsy material. Acta Cytol 1990;34:192-6.
9. Wolber RA, Greene CA, Dupuis BA. Polyclonal carcinoembryonic antigen staining in the cytologic differential diagnosis of primary and metastatic hepatic malignancies. Acta Cytol 1991;35:215-20.
10. Carrozza MJ, Calafati SA, Edmonds PR. Immunocytochemical localization of polyclonal carcinoembryonic antigen in hepatocellular carcinomas. Acta Cytol 1991;35:221-4.
11. Guindi M, Yazdi HM, Gilliatt MA. Fine needle aspiration biopsy of hepatocellular carcinoma. Value of immunocytochemical and ultrastructural studies. Acta Cytol 1994;38: 385-91.
12. Wee A, Nilsson B. pCEA canalicular immunostaining in fine needle aspiration biopsy diagnosis of hepatocellular carcinoma. Acta Cytol 1997;41:1147-55.
13. Salomao DR, Lloyd RV, Goellner JR. Hepatocellular carcinoma: needle biopsy findings in 74 cases. Diagn Cytopathol 1997;16:8-13.
14. Ganjei P, Nadji M, Albores-Saavedra J, Morales AR. Histologic markers in primary and metastatic tumors of the liver. Cancer 1988;62:1994-8.
15. Kojiro M, Kawano Y, Isomura T, Nakashima T. Distribution of albumin and/or alpha-fetoprotein-positive cells in hepatocellular carcinoma. Lab Invest 1981;44:221-6.
16. Chedid A, Chejfec G, Eichorst M, Villamil F, Terg R, Telenta M, et al. Antigenic markers of hepatocellular carcinoma. Cancer 1990;65:84-7.
17. Thung SN, Gerber MA, Sarno E, Popper H. Distribution of five antigens in hepatocellular carcinoma. Lab Invest 1979; 41:101-5.
18. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 1997;10:716-9.
19. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994;118:265-9.
20. Edwards C, Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. J Clin Pathol 1995;48:626-30.
21. Ordonez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-9.